{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:04:12Z","timestamp":1790013852126,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04130-3","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:16:23Z","timestamp":1782933383000},"page":"2829-2842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging Carnitine-functionalized Lipid Nanocarrier based Targeted Delivery of A1874 PROTAC for Glioblastoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Himaxi","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsin","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareena S.","family":"Poonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"4130_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"4130_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11912-009-0002-x","volume":"11","author":"KR Fox","year":"2009","unstructured":"Fox KR. Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer. Curr Oncol Rep. 2009;11:5\u20136.","journal-title":"Curr Oncol Rep"},{"key":"4130_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.pmn.2013.08.002","volume":"15","author":"S Wooden","year":"2014","unstructured":"Wooden S, Docherty S, Plaus K, Kusek A, Vacchiano C. Exploration of specialty certification for nurse anesthetists: nonsurgical pain management as a test case. Pain Manag Nurs. 2014;15:789\u201397.","journal-title":"Pain Manag Nurs"},{"key":"4130_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3\u201314.","journal-title":"NeuroRx"},{"key":"4130_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376\u201381.","journal-title":"Science"},{"key":"4130_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/1570161115666170621084316","volume":"16","author":"TF Whayne","year":"2018","unstructured":"Whayne TF. Medical management and risk reduction of the cardiovascular effects of underwater diving. Curr Vasc Pharmacol. 2018;16:344\u201354.","journal-title":"Curr Vasc Pharmacol"},{"key":"4130_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.wneu.2014.08.033","volume":"83","author":"BR Chaudhary","year":"2015","unstructured":"Chaudhary BR, Fehlings MG. Adult-onset syringomyelia: from theory to practice and beyond. World Neurosurg. 2015;83:462\u20133.","journal-title":"World Neurosurg"},{"key":"4130_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.brachy.2017.11.018","volume":"17","author":"E Poulin","year":"2018","unstructured":"Poulin E, Boudam K, Pinter C, Kadoury S, Lasso A, Fichtinger G, et al. Validation of MRI to TRUS registration for high-dose-rate prostate brachytherapy. Brachytherapy. 2018;17:283\u201390.","journal-title":"Brachytherapy"},{"key":"4130_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","volume":"79","author":"J Hines","year":"2019","unstructured":"Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53. Cancer Res. 2019;79:251\u201362.","journal-title":"Cancer Res"},{"key":"4130_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020;10:207\u201338.","journal-title":"Acta Pharm Sin B"},{"key":"4130_CR11","doi-asserted-by":"crossref","unstructured":"Syahputra EW, Lee H, Cho H, Park HJ, Park KS, Hwang D. PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation. Pharmaceutics. 2025;17.","DOI":"10.3390\/pharmaceutics17040501"},{"key":"4130_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308.","journal-title":"Signal Transduct Target Ther"},{"key":"4130_CR13","doi-asserted-by":"publisher","first-page":"672267","DOI":"10.3389\/fchem.2021.672267","volume":"9","author":"C Cecchini","year":"2021","unstructured":"Cecchini C, Pannilunghi S, Tardy S, Scapozza L. From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation. Front Chem. 2021;9:672267.","journal-title":"Front Chem"},{"key":"4130_CR14","doi-asserted-by":"crossref","unstructured":"Ter Linden E, Abels ER, van Solinge TS, Neefjes J, Broekman MLD. Overcoming barriers in glioblastoma-advances in drug delivery strategies. Cells. 2024;13.","DOI":"10.3390\/cells13120998"},{"key":"4130_CR15","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1039\/D1CS00762A","volume":"51","author":"Y Chen","year":"2022","unstructured":"Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chem Soc Rev. 2022;51:5330\u201350.","journal-title":"Chem Soc Rev"},{"key":"4130_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","volume":"29","author":"SD Edmondson","year":"2019","unstructured":"Edmondson SD, Yang B, Fallan C. Proteolysis targeting chimeras (PROTACs) in \u201cbeyond rule-of-five\u201d chemical space: recent progress and future challenges. Bioorg Med Chem Lett. 2019;29:1555\u201364.","journal-title":"Bioorg Med Chem Lett"},{"key":"4130_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ebiom.2018.06.015","volume":"33","author":"M Salter","year":"2018","unstructured":"Salter M, Corfield E, Ramadass A, Grand F, Green J, Westra J, et al. Initial identification of a blood-based chromosome conformation signature for aiding in the diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine. 2018;33:169\u201384.","journal-title":"EBioMedicine"},{"key":"4130_CR18","first-page":"1921","volume":"49","author":"NH Farizan","year":"2020","unstructured":"Farizan NH, Sutan R, Mani KK. Effectiveness of \u201cBe SAFE Drowning Prevention and Water Safety Booklet\u201d intervention for parents and guardians. Iran J Public Health. 2020;49:1921\u201330.","journal-title":"Iran J Public Health"},{"key":"4130_CR19","doi-asserted-by":"crossref","unstructured":"Richards T, Patel H, Patel K, Schanne F. Endogenous lipid carriers-bench-to-bedside roadblocks in production and drug loading of exosomes. Pharmaceuticals (Basel). 2023;16.","DOI":"10.3390\/ph16030421"},{"key":"4130_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","volume":"23","author":"D Chenthamara","year":"2019","unstructured":"Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:20.","journal-title":"Biomater Res"},{"key":"4130_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71.","journal-title":"J Nanobiotechnol"},{"key":"4130_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","volume":"29","author":"CW Pouton","year":"2006","unstructured":"Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278\u201387.","journal-title":"Eur J Pharm Sci"},{"key":"4130_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jvoice.2013.08.006","volume":"28","author":"PE Kwak","year":"2014","unstructured":"Kwak PE, Stasney CR, Hathway J, Minard CG, Ongkasuwan J. Knowledge, experience, and anxieties of young classical singers in training. J Voice. 2014;28:191\u20135.","journal-title":"J Voice"},{"key":"4130_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/jobm.201400621","volume":"55","author":"JC Lim","year":"2015","unstructured":"Lim JC, Goh KM, Shamsir MS, Ibrahim Z, Chong CS. Characterization of aluminum resistant Anoxybacillus sp. SK 3-4 isolated from a hot spring. J Basic Microbiol. 2015;55:514\u20139.","journal-title":"J Basic Microbiol"},{"key":"4130_CR25","doi-asserted-by":"crossref","unstructured":"Patki M, Giusto K, Gorasiya S, Reznik SE, Patel K. 17-alpha hydroxyprogesterone nanoemulsifying preconcentrate-loaded vaginal tablet: a novel non-invasive approach for the prevention of preterm birth. Pharmaceutics. 2019;11.","DOI":"10.3390\/pharmaceutics11070335"},{"key":"4130_CR26","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1166\/jbn.2013.1710","volume":"9","author":"K Patel","year":"2013","unstructured":"Patel K, Patil A, Mehta M, Gota V, Vavia P. Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol. J Biomed Nanotechnol. 2013;9:1996\u20132006.","journal-title":"J Biomed Nanotechnol"},{"key":"4130_CR27","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.omtn.2024.102292","volume":"35","author":"A Saraswat","year":"2024","unstructured":"Saraswat A, Vemana HP, Dukhande V, Patel K. Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers. Mol Ther Nucleic Acids. 2024;35:102292.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4130_CR28","doi-asserted-by":"publisher","first-page":"126413","DOI":"10.1016\/j.ijbiomac.2023.126413","volume":"252","author":"R Vartak","year":"2023","unstructured":"Vartak R, Deore B, Sanhueza CA, Patel K. Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations. Int J Biol Macromol. 2023;252:126413.","journal-title":"Int J Biol Macromol"},{"key":"4130_CR29","doi-asserted-by":"publisher","first-page":"843829","DOI":"10.3389\/fphar.2022.843829","volume":"13","author":"XD Dong","year":"2022","unstructured":"Dong XD, Zhang M, Cai CY, Teng QX, Wang JQ, Fu YG, et al. Overexpression of ABCB1 associated with the resistance to the KRAS-G12C specific inhibitor ARS-1620 in cancer cells. Front Pharmacol. 2022;13:843829.","journal-title":"Front Pharmacol"},{"key":"4130_CR30","doi-asserted-by":"publisher","first-page":"640957","DOI":"10.3389\/fcell.2021.640957","volume":"9","author":"ZN Lei","year":"2021","unstructured":"Lei ZN, Teng QX, Gupta P, Zhang W, Narayanan S, Yang DH, et al. Cabozantinib reverses topotecan resistance in human Non-Small Cell Lung Cancer NCI-H460\/TPT10 cell line and tumor xenograft model. Front Cell Dev Biol. 2021;9:640957.","journal-title":"Front Cell Dev Biol"},{"key":"4130_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1208\/s12249-024-02978-5","volume":"25","author":"H Patel","year":"2024","unstructured":"Patel H, Patel A, Vats M, Patel K. Albumin and Polysorbate-80 Coated Sterile Nanosuspensions of Mebendazole for Glioblastoma Therapy. AAPS PharmSciTech. 2024;25:271.","journal-title":"AAPS PharmSciTech"},{"key":"4130_CR32","doi-asserted-by":"publisher","first-page":"8596","DOI":"10.1021\/acs.jmedchem.1c01946","volume":"65","author":"A Thakur","year":"2022","unstructured":"Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, et al. Glioblastoma: current status, emerging targets, and recent advances. J Med Chem. 2022;65:8596\u2013685.","journal-title":"J Med Chem"},{"key":"4130_CR33","doi-asserted-by":"publisher","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780.","journal-title":"Pharmacol Res"},{"key":"4130_CR34","doi-asserted-by":"crossref","unstructured":"Alphandery E. Nano-therapies for glioblastoma treatment. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12010242"},{"key":"4130_CR35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3109\/09687688.2010.521200","volume":"27","author":"B Yu","year":"2010","unstructured":"Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27:286\u201398.","journal-title":"Mol Membr Biol"},{"key":"4130_CR36","first-page":"741","volume":"2","author":"HW Li Xu","year":"2022","unstructured":"Li Xu HW, Chu Z, Cai L, Shi H, Zhu C, Pan D, et al. Temperature-responsive multilayer films of micelle-based composites for controlled release of a third-generation EGFR inhibitor. ACS Appl Polym Mater. 2022;2:741\u201350.","journal-title":"ACS Appl Polym Mater"},{"key":"4130_CR37","doi-asserted-by":"crossref","unstructured":"Postges F, Kayser K, Appelhaus J, Monschke M, Gutschow M, Steinebach C, et al. \"Solubility enhanced formulation approaches to overcome oral delivery obstacles of PROTACs. Pharmaceutics. 2023;15.","DOI":"10.3390\/pharmaceutics15010156"},{"key":"4130_CR38","unstructured":"[Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/022249Orig1s015.pdf. Accessed on 03\/10\/2025."},{"key":"4130_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/fon.10.157","volume":"7","author":"A Piunti","year":"2011","unstructured":"Piunti A, Pasini D. Epigenetic factors in cancer development: polycomb group proteins. Future Oncol. 2011;7:57\u201375.","journal-title":"Future Oncol"},{"key":"4130_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1348-0421.1995.tb02234.x","volume":"39","author":"M Asano","year":"1995","unstructured":"Asano M, Nakane A, Kohanawa M, Minagawa T. Sequential involvement of NK cells and CD8+ T cells in granuloma formation of Rhodococcus aurantiacus-infected mice. Microbiol Immunol. 1995;39:499\u2013507.","journal-title":"Microbiol Immunol"},{"key":"4130_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.aquatox.2008.04.004","volume":"88","author":"Y Jin","year":"2008","unstructured":"Jin Y, Wang W, Xu C, Fu Z, Liu W. Induction of hepatic estrogen-responsive gene transcription by permethrin enantiomers in male adult zebrafish. Aquat Toxicol. 2008;88:146\u201352.","journal-title":"Aquat Toxicol"},{"key":"4130_CR42","doi-asserted-by":"crossref","unstructured":"Doellman MM, Ragland GJ, Hood GR, Meyers PJ, Egan SP, Powell THQ et al. \"Genomic differentiation during speciation-with-gene-flow: comparing geographic and host-related variation in divergent life history adaptation in rhagoletis pomonella. Genes (Basel). 2018;9.","DOI":"10.3390\/genes9050262"},{"key":"4130_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00392-014-0726-y","volume":"103","author":"P Sabouret","year":"2014","unstructured":"Sabouret P, Depret-Bixio L, Cotte FE, Marie P, Bedira N, Blin P. Sex differences in stroke prevention in atrial fibrillation in French primary care. results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol. 2014;103:887\u201393.","journal-title":"Clin Res Cardiol"},{"key":"4130_CR44","doi-asserted-by":"publisher","first-page":"122163","DOI":"10.1016\/j.ijpharm.2022.122163","volume":"626","author":"S Daware","year":"2022","unstructured":"Daware S, Patki M, Saraswat A, Palekar S, Patel K. Development of a safe pediatric liquisolid self-nanoemulsifying system of triclabendazole for the treatment of fascioliasis. Int J Pharm. 2022;626:122163.","journal-title":"Int J Pharm"},{"key":"4130_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/03639045.2018.1546311","volume":"45","author":"M Patki","year":"2019","unstructured":"Patki M, Patel K. Development of a solid supersaturated self-nanoemulsifying preconcentrate (S-superSNEP) of fenofibrate using dimethylacetamide and a novel co-processed excipient. Drug Dev Ind Pharm. 2019;45:405\u201314.","journal-title":"Drug Dev Ind Pharm"},{"key":"4130_CR46","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.bmcl.2018.03.057","volume":"28","author":"R Rai","year":"2018","unstructured":"Rai R, Dutta RK, Singh S, Yadav DK, Kumari S, Singh H, et al. Synthesis, biological evaluation and molecular docking study of 1-amino-2-aroylnaphthalenes against prostate cancer. Bioorg Med Chem Lett. 2018;28:1574\u201380.","journal-title":"Bioorg Med Chem Lett"},{"key":"4130_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/10717544.2019.1710623","volume":"27","author":"L Kou","year":"2020","unstructured":"Kou L, Sun R, Xiao S, Cui X, Sun J, Ganapathy V, et al. OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug delivery in vitro, in situ, and in vivo. Drug Deliv. 2020;27:170\u20139.","journal-title":"Drug Deliv"},{"key":"4130_CR48","first-page":"1605","volume":"46","author":"L Kou","year":"2018","unstructured":"Kou L, Hou Y, Yao Q, Guo W, Wang G, Wang M, et al. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation\/carnitine transporter OCTN2. Artif Cells Nanomed Biotechnol. 2018;46:1605\u201316.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4130_CR49","doi-asserted-by":"crossref","unstructured":"de la Harpe KM, Kondiah PPD, Choonara YE, Marimuthu T, du Toit LC, Pillay V. The hemocompatibility of nanoparticles: a review of cell-nanoparticle interactions and hemostasis. Cells. 2019;8.","DOI":"10.3390\/cells8101209"},{"key":"4130_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4939-7352-1_9","volume":"1682","author":"BW Neun","year":"2018","unstructured":"Neun BW, Ilinskaya AN, Dobrovolskaia MA. Updated method for in vitro analysis of nanoparticle hemolytic properties. Methods Mol Biol. 2018;1682:91\u2013102.","journal-title":"Methods Mol Biol"},{"key":"4130_CR51","doi-asserted-by":"publisher","first-page":"e2409753","DOI":"10.1002\/advs.202409753","volume":"11","author":"L Yi","year":"2024","unstructured":"Yi L, Zhang Z, Zhou W, Zhang Y, Hu Y, Guo A, et al. BRD4 degradation enhanced glioma sensitivity to Temozolomide by regulating Notch1 via Glu-modified GSH-responsive nanoparticles. Adv Sci. 2024;11:e2409753.","journal-title":"Adv Sci"},{"key":"4130_CR52","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1021\/acsbiomaterials.0c00020","volume":"6","author":"C He","year":"2020","unstructured":"He C, Jin Y, Deng Y, Zou Y, Han S, Zhou C, et al. Efficient oral delivery of poorly water-soluble drugs using Carnitine\/Organic Cation Transporter 2-mediated polymeric micelles. ACS Biomater Sci Eng. 2020;6:2146\u201358.","journal-title":"ACS Biomater Sci Eng"},{"key":"4130_CR53","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14728222.2018.1502273","volume":"22","author":"L Kou","year":"2018","unstructured":"Kou L, Sun R, Ganapathy V, Yao Q, Chen R. Recent advances in drug delivery via the Organic Cation\/Carnitine Transporter 2 (OCTN2\/SLC22A5). Expert Opin Ther Targets. 2018;22:715\u201326.","journal-title":"Expert Opin Ther Targets"},{"key":"4130_CR54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/10717544.2020.1748762","volume":"27","author":"T Yang","year":"2020","unstructured":"Yang T, Feng J, Zhang Q, Wu W, Mo H, Huang L, et al. l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. Drug Deliv. 2020;27:575\u201384.","journal-title":"Drug Deliv"},{"key":"4130_CR55","doi-asserted-by":"publisher","first-page":"30321","DOI":"10.1021\/acsomega.2c03591","volume":"7","author":"L Xu","year":"2022","unstructured":"Xu L, Chu Z, Zhang J, Cai T, Zhang X, Li Y, et al. Steric effects in the deposition mode and drug-delivering efficiency of nanocapsule-based multilayer films. ACS Omega. 2022;7:30321\u201332.","journal-title":"ACS Omega"},{"key":"4130_CR56","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41419-020-03015-6","volume":"11","author":"AC Qin","year":"2020","unstructured":"Qin AC, Jin H, Song Y, Gao Y, Chen YF, Zhou LN, et al. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death Dis. 2020;11:80.","journal-title":"Cell Death Dis"},{"key":"4130_CR57","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.neo.2019.10.003","volume":"21","author":"C Otto","year":"2019","unstructured":"Otto C, Schmidt S, Kastner C, Denk S, Kettler J, Muller N, et al. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. Neoplasia. 2019;21:1110\u201320.","journal-title":"Neoplasia"},{"key":"4130_CR58","doi-asserted-by":"publisher","first-page":"117159","DOI":"10.1016\/j.bcp.2025.117159","volume":"241","author":"J Hu","year":"2025","unstructured":"Hu J, Yang J, Zhou R, Chen K, Zhao H, Zhou Y. Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. Biochem Pharmacol. 2025;241:117159.","journal-title":"Biochem Pharmacol"},{"key":"4130_CR59","doi-asserted-by":"crossref","unstructured":"Jo H, Lee S, Kim MH, Park S, Lee SY. Recapitulating glioma stem cell niches using 3D spheroid models for glioblastoma research. Biosensors (Basel). 2024;14.","DOI":"10.3390\/bios14110539"},{"key":"4130_CR60","doi-asserted-by":"crossref","unstructured":"Nayak P, Bentivoglio V, Varani M, Signore A. Three-dimensional in vitro tumor spheroid models for evaluation of anticancer therapy: recent updates. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15194846"},{"key":"4130_CR61","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.tips.2020.08.008","volume":"41","author":"T Minko","year":"2020","unstructured":"Minko T. Nanoformulation of BRD4-degrading PROTAC: improving druggability to target the \u201cundruggable\u201d MYC in pancreatic cancer. Trends Pharmacol Sci. 2020;41:684\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"4130_CR62","doi-asserted-by":"crossref","unstructured":"Patel A, Saraswat A, Patel H, Chen ZS, Patel K. Palmitoyl carnitine-anchored nanoliposomes for neovasculature-specific delivery of gemcitabine elaidate to treat pancreatic cancer. Cancers (Basel). 2022;15.","DOI":"10.3390\/cancers15010182"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04130-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:02:35Z","timestamp":1790010155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04130-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04130-3","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"One-way ANOVA followed by Dunnett\u2019s multiple comparison test was used for statistical analysis. Significance is denoted as: *\n                      p\n                      \u2009<\u20090.05, **\n                      p\n                      \u2009<\u20090.01, ***\n                      p\n                      \u2009<\u20090.001, ****\n                      p\n                      \u2009<\u20090.0001,\n                      ns\n                      \u2009=\u2009not significant.","order":1,"name":"Ethics","label":"Statistical Analysis","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}